Implantable atrial defibrillator and detection of atrial flutter.
The implantable atrial defibrillator (IAD) is designed to detect and treat atrial fibrillation (AF) with low energy synchronized shocks. A patient with a history of persistent AF was implanted with an IAD after ineffective treatment with procainamide and sotalol. Through four months of follow-up, the IAD performed appropriate detection and treatment of AF. During the fifth month, the patient was put on flecainide in an attempt to minimize the AF recurrence rate. On flecainide the patient experienced typical atrial flutter which required IAD reprogramming for appropriate detection and therapy delivery. This case report examines the optimization of the IAD to detect atrial flutter. Six months of follow-up after optimization the IAD has shown appropriate detection of both atrial flutter and AF. During the entire follow-up period the IAD had appropriate detection of sinus rhythm (no false positive detection, i.e. sinus rhythm as AF).
Schwartz
M
M
Guidant, Inc. St. Paul, MN; St Luke's Medical Center, Milwaukee, WI, USA.
Maglio
C
C
Akhtar
M
M
Sra
J
J
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000628:therapy*; D001282:Atrial Flutter / Q000139:chemically induced / Q000628:therapy*; D017147:Defibrillators, Implantable; D004562:Electrocardiography; D005260:Female; D005424:Flecainide / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D055502:Secondary Prevention
D000889:Anti-Arrhythmia Agents; D005424:Flecainide